Ignite Creation Date:
2025-12-25 @ 2:16 AM
Ignite Modification Date:
2025-12-26 @ 7:15 PM
Study NCT ID:
NCT00122460
Status:
COMPLETED
Last Update Posted:
2014-07-23
First Post:
2005-07-19
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)
Sponsor:
Merck KGaA, Darmstadt, Germany
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2004-12
Start Date Type:
None
Primary Completion Date:
2007-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2011-01
Completion Date Type:
ACTUAL
First Submit Date:
2005-07-19
First Submit QC Date:
None
Study First Post Date:
2005-07-22
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2011-08-25
Results First Submit QC Date:
None
Results First Post Date:
2011-09-30
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2014-07-11
Last Update Post Date:
2014-07-23
Last Update Post Date Type:
ESTIMATED